ACTONEL Drug Patent Profile

When do Actonel patents expire, and when can generic versions of Actonel launch?

Actonel is a drug marketed by Apil and Warner Chilcott and is included in two NDAs.

The generic ingredient in ACTONEL is calcium carbonate; risedronate sodium. There are two hundred and eighty-two drug master file entries for this compound. Additional details are available on the calcium carbonate; risedronate sodium profile page.

Summary for ACTONEL

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	35
Patent Applications:	2,880
Drug Prices:	Drug price information for ACTONEL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACTONEL
What excipients (inactive ingredients) are in ACTONEL?	ACTONEL excipients list
DailyMed Link:	ACTONEL at DailyMed

See drug prices for ACTONEL

See drug sales revenues for ACTONEL

Recent Clinical Trials for ACTONEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dong-A ST Co., Ltd.	Phase 4
Wake Forest University Health Sciences	Phase 3
The New York Community Trust	Phase 4

See all ACTONEL clinical trials

Pharmacology for ACTONEL

Drug Class

Bisphosphonate

Paragraph IV (Patent) Challenges for ACTONEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ACTONEL	Tablets	risedronate sodium	150 mg	020835	1	2008-08-12
ACTONEL	Tablets	risedronate sodium	75 mg	020835	1	2007-09-07
ACTONEL	Tablets	risedronate sodium	5 mg, 30 mg and 35 mg	020835	1	2004-04-23

US Patents and Regulatory Information for ACTONEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-002	Apr 14, 2000		DISCN	Yes	No
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-004	Apr 16, 2007		DISCN	Yes	No
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-001	Mar 27, 1998		DISCN	Yes	No
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-003	May 25, 2002	AB	RX	Yes	Yes
Warner Chilcott	ACTONEL WITH CALCIUM (COPACKAGED)	calcium carbonate; risedronate sodium	TABLET;ORAL	021823-001	Aug 12, 2005		DISCN	Yes	No
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-005	Apr 22, 2008	AB	RX	Yes	Yes

Expired US Patents for ACTONEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-002	Apr 14, 2000
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-001	Mar 27, 1998
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-001	Mar 27, 1998
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-002	Apr 14, 2000

International Patents for ACTONEL

See the table below for patents covering ACTONEL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	61370
Australia	5153485
Australia	587001
Canada	1320727	COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DIPHOSPHONATES GEMINAUX (PHARMACEUTICAL COMPOSITIONS CONTAINING GEMINAL DIPHOSPHONATES)
Germany	10075030
Germany	3582033
Denmark	168754

Supplementary Protection Certificates for ACTONEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0186405	SPC/GB00/021	United Kingdom		PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
0186405	C300031	Netherlands		PRODUCT NAME: RISEDRONINEZUUR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF FARMACEUTISCH AANVAARDBARE ESTER, IN HET BIJZONDER NATRIUMRISEDRONAAT; NAT REGISTRATION NO/DATE: RVG 24990 20000609; FIRST REGISTRATION: SE 15290 - 15297 19991007
0186405	2000C/028	Belgium		PRODUCT NAME: NATRIUMRISEDRONAAT; NAT. REGISTRATION NO/DATE: 354 IS 498 F3 20000508; FIRST REGISTRATION: SE 15290 19991007
0998292	CA 2006 00005	Denmark		PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, COLECALCIFEROL
0998292	PA2006002	Lithuania		PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
0998292	91222	Luxembourg		91222, EXPIRES: 20200824
0998292	PA2006002,C0998292	Lithuania		PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824

ACTONEL (risedronate) market dynamics and financial trajectory: exclusivity, generic risk, and revenue exposure

Last updated: July 23, 2026

ACTONEL (risedronate) is a mature osteoporosis product with shrinking market share driven by broad generic availability and long-running payer preference. Financial trajectory is dominated by (1) post-loss-of-exclusivity volume shift to lower-cost generics, (2) geographic heterogeneity in generic penetration, and (3) ongoing utilization management for oral bisphosphonates. In most developed markets, ACTONEL’s topline trajectory has been structurally downward since patent and exclusivity expiry, with remaining revenue attributable to brand persistence in fewer geographies and to dose-form specific adoption where generics lag.

How has ACTONEL’s market evolved since generic launch?

The market for oral bisphosphonates in osteoporosis has consolidated around cost-effective dosing regimens. ACTONEL competes within a class where payer formularies commonly require generic risedronate, generic alendronate, or generic ibandronate and use step edits by fracture-risk and adherence considerations.

What are the main demand drivers for oral bisphosphonates like ACTONEL

• Osteoporosis prevalence and fracture incidence trends (ageing populations increase eligible patients).
• Adherence and persistence across monthly vs weekly regimens.
• Guideline updates that influence first-line selection (often favoring bisphosphonates with strong dosing convenience and low total cost).
• Safety and tolerability perceptions, including GI tolerance and rare complications that steer selection toward alternative agents.

What are the supply-side dynamics

• Generic penetration typically accelerates after patent expiry and successful ANDA approvals, with multiple manufacturers entering rapidly.
• Price compression follows because oral solid dose products have low switching barriers once bioequivalence is established.
• Store-brand and pharmacy network contracting reduce net-to-gross even where multiple generic SKUs exist.

What is the financial trajectory for ACTONEL versus competitors (alendronate, ibandronate) after exclusivity?

ACTONEL’s brand economics follow a standard branded-to-generic curve: peak under brand exclusivity, then steep margin compression as generic risedronate takes share and brand marketing yields diminishing returns.

Competitive positioning dynamics

• Alendronate (oral weekly) and ibandronate (oral monthly) often gain payer preference based on dosing frequency and negotiated pricing.
• Risedronate’s differentiator historically included specific dosing options and tolerability profiles in labeled subpopulations, but these rarely offset pricing once generics dominate.

Key financial implications

• Net revenue decline typically reflects both volume loss and price erosion.
• Operating income declines faster than revenue because brand selling costs and channel rebates persist during transition.
• Any residual brand value usually concentrates in smaller geographies, specific NDCs with slower generic uptake, or payer segments with legacy formulary positioning.

When does ACTONEL lose exclusivity and what does that do to pricing and volume?

For ACTONEL, exclusivity loss effects are the primary inflection that drives the financial trajectory. Once primary and secondary patent barriers fall away, generic competition compresses brand pricing and reduces brand unit share.

How exclusivity expiry translates into market outcomes

• Filing-to-approval cycle: a time lag exists between ANDA submissions and market entry.
• Post-launch: rapid generic entry increases competitive bidding intensity and forces brand rebates upward.
• Post-penetration: net pricing continues to fall as pharmacies and PBMs switch to lowest-cost equivalents.

What is the generic entry risk for ACTONEL by dose form and regimen?

ACTONEL is not a single product in practice. Risk is highest for the most commonly prescribed oral strengths and regimens where multiple ANDAs are likely.

Risk hotspots that accelerate brand decline

• Once generics cover the core daily and weekly risedronate presentations, payer switching is immediate.
• If any brand SKUs (e.g., specific package sizes or less-used strengths) have slower generic coverage, brand may retain a short tail, but overall revenue remains pressured.

What patents protect ACTONEL and how strong is the patent estate?

ACTONEL’s patent estate historically spanned composition and formulation/method-of-use protections, but the business reality is that long-term exclusivity has already expired in major markets. The current market structure reflects that generics are established and have scaled.

Why the patent estate matters less after generic scaling

• Litigation and settlement can delay entry, but once entry occurs and multiple competitors are active, brand economics become a pricing problem more than an IP problem.
• Residual barriers typically protect specific incremental changes rather than the core risedronate molecule, limiting their ability to sustain brand margins.

What patent litigation affects ACTONEL generics and can it change the financial curve?

In mature products like ACTONEL, litigation history generally affects timing rather than permanently preserving brand exclusivity. Where settlements exist, they usually create entry windows rather than long-term barriers.

Settlement-driven market outcomes

• Delayed ANDA launch can temporarily protect unit share and net price.
• Once delayed entrants join, the market typically returns to a low-cost equilibrium quickly because oral bisphosphonates are interchangeable in payer logic.

What is the Orange Book status of ACTONEL?

Orange Book status is the operational proxy for who controls what and when. For a mature bisphosphonate brand, Orange Book listings generally show expiring or expired entries, consistent with broad generic availability and established competition.

Featured snippet answer

ACTONEL’s Orange Book controls for the branded product have largely run through, with generics now the dominant competitive reality in most developed markets.

How does FDA status and labeling influence ACTONEL utilization and revenue?

Even after patent expiry, labeling and FDA status shape prescribing persistence and payer access.

What labeling factors influence switching

• Indication boundaries (postmenopausal osteoporosis, prevention/treatment contexts).
• Risk-benefit framing for fracture prevention.
• Concomitant therapies and monitoring requirements that can influence clinician choice.

Which companies are challenging ACTONEL and how many ANDAs typically enter?

For established osteoporosis brands, generic manufacturers usually file multiple ANDAs with rapid follow-on entry after first approvals.

Business impact of multi-entrant generic competition

• More entrants increases price competition and reduces brand share faster.
• PBMs use rebates and contracting leverage to favor lowest net cost, accelerating brand margin erosion.

How does ACTONEL compare with alendronate and ibandronate on market dynamics?

Side-by-side market logic

• Alendronate: weekly convenience often improves formulary access economics and persistence.
• Ibandronate: monthly dosing can win where adherence targeting is strong and net pricing is favorable.
• Risedronate (ACTONEL): competes on labeled nuances and dosing options, but generics remove the economic premium after exclusivity.

Practical conclusion

Across most reimbursement ecosystems, brand-to-generic transition has been more decisive for ACTONEL’s revenue path than incremental clinical differentiation.

What commercial strategy options remain for ACTONEL after exclusivity?

Once generics dominate, branded strategy typically shifts to (1) maximizing remaining formulary listings in specific PBMs, (2) targeting specific patient segments where persistence was historically stronger, and (3) maintaining competitive rebates rather than expanding market.

What works commercially in the generic era

• Contracting with PBMs for preferred coverage using rebate structures.
• Focused marketing tied to adherence support and clinician education.
• Ensuring supply reliability across core NDCs to prevent substitution during shortages.

What are the likely future market dynamics for ACTONEL?

For an oral generic-dominated segment, forward-looking dynamics are mainly cost minimization and incremental adherence management, rather than major clinical disruption.

Key forward drivers

• Continued price erosion as competitors refresh contracts.
• Shifts in formulary protocols toward lower-cost agents and preferred dosing schedules.
• Patient migration to non-oral options (injectables, infusion bisphosphonates) when cost and outcomes align, which can further reduce the oral market ceiling.

Key Takeaways

• ACTONEL’s financial trajectory is structurally constrained by generic competition and payer switching behavior.
• Market dynamics after exclusivity loss typically show rapid net price compression, sustained volume share erosion, and eventual revenue stabilization at a lower brand baseline in niche geographies or lag-covered SKUs.
• Future revenue headroom, where it exists, is tied to contracting persistence rather than IP protection.

FAQs

1. How fast does generic risedronate typically take share after ANDA approval for osteoporosis products?
2. Do payers prefer weekly alendronate over monthly ibandronate, and what does that do to risedronate demand?
3. Can brand rebates meaningfully preserve ACTONEL revenue after generic entry?
4. Which ACTONEL dose forms are most vulnerable to substitution under formulary switching?
5. How do oral bisphosphonate utilization management rules affect long-term brand revenue trajectories?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (risedronate-related listings). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm